Tag Archives: Liana Moussatos

Wedbush Thinks ObsEva SA’s Stock is Going to Recover

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on ObsEva SA (OBSV – Research Report), with a price target of $38. The company’s shares opened today at $10.77, close to its 52-week low of $9.73.

Eiger Biopharmaceuticals (EIGR) Gets a Buy Rating from Wedbush

Wedbush analyst Liana Moussatos maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report) today and set a price target of $35. The company’s shares opened today at $11.36. According to TipRanks.com, Moussatos ‘ ranking currently consits of no

Wedbush Remains a Buy on Global Blood Therapeutics (GBT)

Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT – Research Report) today and set a price target of $107. The company’s shares closed on Friday at $53.98. According to TipRanks.com, Moussatos is currently ranked with

Wedbush Thinks Lexicon Pharmaceuticals’ Stock is Going to Recover

Wedbush analyst Liana Moussatos reiterated a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $35. The company’s shares opened today at $5.38, close to its 52-week low of $4.25. According to TipRanks.com,

Wedbush Believes Global Blood Therapeutics (NASDAQ: GBT) Still Has Room to Grow

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Global Blood Therapeutics (GBT – Research Report), with a price target of $107. The company’s shares closed on Friday at $60.78, close to its 52-week high

Wedbush Thinks Zafgen’s Stock is Going to Recover

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Zafgen (ZFGN – Research Report), with a price target of $6. The company’s shares opened today at $2.29, close to its 52-week low of $1.88. According